Thus, the DDNDBeQ formulation provides significant benefits over unconjugated VCP inhibitor drugs, to control NSCLC progression and has the potential for further development to allow tumor-targeted sustained drug delivery. This evidence concerns the gene VCP and non-small cell lung carcinoma.